42 results about "Chemerin" patented technology

This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction of levels of inflammatory mediators.

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-3 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, proliferation of breast cancer cells can be inhibited, the cell cycle of the breast cancer cells is blocked, apoptosis of the breast cancer cells is promoted, effective micromolecule treatment drugs are provided for female reproductive diseases such as breast cancer, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.

The invention provides, inter alia, methods for monitoring the differentiation state of cultured cells, such as cultured MSCs, as well as related kits and systems for performing the methods. In certain embodiments, the methods entail measuring the level of one or more of KLF5, FABP4, Adiponectin/ADIPOQ, Chemerin/RARRES2, KLF4, PAI1, Runx2, ALPL, Osteocalcin/BGLAP, CTNNB1, Osteonectin/SPARC, Sox9, COL2A1, MIA, and COMP.

The invention belongs to the technical field of testing or analyzing materials by means of chemical or physical properties of a measuring material, and discloses a method for measuring the regulationand control of Chemerin on insulin resistance and the intervention of a CMKLR1 agonist, which comprises the following steps: preparing a pancreatic diabetes model by adopting an arginine induction method, performing intraperitoneal injection of 350 mg/kg arginine once a day for 6 weeks, and establishing a pancreatic diabetes group by a mouse common diet; during the period, establishing a pancreas-derived diabetes mellitus group by the common diet of the mice;meanwhile, establishing a high-fat diet group by adopting a formula feed open diet; establishinga negative control group, wherein the mice are fed with ordinary diet and water for 6 weeks; adopting a general pathology, an enzyme-linked immunosorbent assay, a Real-Time PCR method and an intraperitoneal injection glucose tolerance test for detection; expressing all the detection data by mean plus or minus standard deviation, and testing the normal distribution is by Shapiro Wilk test; using single-factor variance analysis to comparegroups with each other, and if the groups do not conform to the normal distribution, using Mann-Whitney U test for comparison; significant difference lying in P < 0.05; applying SPSS 22.0 for Windowssoftware to implement the entire verification process.

The invention discloses a CMKLR1 antagonistic polypeptide and derivatives and application thereof, and particularly relates to analogs of the CMKLR1 antagonistic polypeptide shown in sequences SEQ IDNO.1-21 and derivatives thereof. The derivatives of the binding peptide are products obtained after conventional modification of amino terminals or carboxyl terminals on CMKLR1 binding peptide amino acid side chain groups and CMKLR1 antagonistic polypeptide fragments or products obtained by bonding labels for polypeptide or protein detection or purification with the CMKLR1 antagonistic polypeptide. The binding peptide and the derivatives thereof can be bonded with CMKLR1 in vitro, and by blocking the bond of chemerin/RvE1 and CMKLR1, cAMP concentration increase is promoted, calcium influx caused by chemerin is inhibited, cell chemotaxis caused by chemerin is inhibited, and effective small-molecular treatment drugs are provided for high-expression CMKLR1 receptor diseases such as breast cancer and polycystic ovarian syndrome.

The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.

The invention discloses a CMKLR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a CMKLR1 antagonistic polypeptide shown in SEQ ID No.1-24 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a CMKLR1 binding peptide amino acid side chain group and an amino terminal or a carboxyl terminal of a CMKLR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the CMKLR1antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with CMKLR1 in vitro, by stopping combination of chemerin/RvE1 and CMKLR1, increase of the cAMP concentrationis promoted, the calcium influx caused by chemerin and cell chemotaxis caused by chemerin are inhibited, proliferation of ovarian carcinoma cells can be inhibited, apoptosis of the ovarian carcinoma cells is promoted, and effective micromolecule treatment drugs are provided for female reproductive diseases such as ovarian cancer.

The invention relates to a detection test strip for chemerin and a derivative polypeptide thereof and a preparation method of the detection test strip and in particular discloses a test strip for detecting chemerin. The detection test strip comprises a detection film, wherein a binding region containing a first antibody marked by a marker is arranged at the upstream of the detection film, a sample adding region is arranged at the upstream of the binding region, the detection film is provided with a detection region and a control region, and the control region is arranged at the downstream of the detection region; a second antibody coats the detection region, and a secondary antibody containing the first antibody coats the control region; and the first antibody and the second antibody can be respectively and specifically bound with chemerin. The detection test strip provided by the invention is convenient, quick and economic and can realize semi quantitation.

The invention discloses a method for detecting single nucleotide polymorphism of a cattle chemerin gene. Gene polymorphism comprises A or G base polymorphism in the 868th site of the cattle chemerin gene and G or A base polymorphism in the 1021st site of the cattle chemerin gene. The detection method for the single nucleotide polymorphism of the cattle chemerin gene comprises the following steps of: by using a cattle entire genome DNA (deoxyribonucleic acid) to be detected, containing a chemerin gene, as a template, and a primer pair (comprising P and newP) as primers, carrying out PCR (Polymerase Chain Reaction) amplification on the cattle chemerin gene; after a PCR amplified product is digested by using restriction enzyme Pvu II, carrying out agarose gel electrophoresis on an amplified fragment subjected to enzyme digestion; and identifying the single nucleotide polymorphism of the 868th site and the 1021st site of the cattle chemerin gene according to an agarose gel electrophoresis result. The method is used for screening and detecting a molecular genetic marker which is closely related to cattle production trait on the basis of a DNA level, carrying out marker assisted selection (MAS) on Chinese cattle beef growth trait and quickly establishing cattle specie groups with favorable genetic resources.

Disclosed are pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug. Each pharmaceutical composition comprises a chemokine analogue peptide, the chemokine analogue peptide is selected from SEQ ID NO. 1; and a medicament. The medicament is selected from one or more of the targeted drugs, carriers, adjuvants, and excipients. Compared with administering targeted drugs alone, the pharmaceutical composition of the present invention can overcome the drug resistance of anti-cancer drugs, and when applied to drug-resistant cancers, the invention can increase the effect of treating cancer and inhibiting tumor growth and reduce the side effects in the process of cancer treatment, can more effectively treat cancer and inhibit tumor growth.

The invention provides application of GPR1 (G protein coupled receptor 1) target and its antagonist in infertility-related diseases. It is determined herein that the chemerin/GPR1 system is a novel target to regulate polycystic ovarian syndrome, is closely associated with mTOR signal pathway associated with the activation of primordial follicles, and may involve in the process of regulating the activation of primordial follicles. The invention also provides application GPR1 gene or GPR1 protein in screening drugs and diagnostic targets to treat or prevent ovulatory obstacle and related diseases, and discloses application of a GPR1 gene or GPR1 protein antagonist in the prevention or treatment of ovulatory obstacle and related diseases.

Recombinant oncolytic viruses (OVs) that express one or more metabolic modulator proteins, such as an adipokine (e.g., leptin or chemerin), insulin, and/or IGF- 1, and methods of their use to treat cancer, for example in immunotherapy anti-cancer treatments. In some examples, such recombinant OVs and methods increase T cell infiltration into the tumor or tumor microenvironment.

The invention discloses a CMKLR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a CMKLR1 antagonistic polypeptide shown in SEQ ID No.1-15 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a CMKLR1 binding peptide amino acid side chain group and an amino terminal or a carboxyl terminal of a CMKLR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the CMKLR1antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with CMKLR1 in vitro, by stopping combination of chemerin/RvE1 and CMKLR1, the cAMP concentration is changed,the calcium influx caused by chemerin and cell chemotaxis caused by chemerin are inhibited, proliferation of ovarian carcinoma cells can be inhibited, apoptosis of the ovarian carcinoma cells is promoted, and effective micromolecule treatment drugs are provided for female reproductive diseases.

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-7 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, effective micromolecule treatment drugs are provided for diseases, such as breast cancer, of high-expression GPR1 receptors, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-4 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, effective micromolecule treatment drugs are provided for diseases, such as breast cancer, of high-expression GPR1 receptors, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-7 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, effective micromolecule treatment drugs are provided for diseases, such as breast cancer, of high-expression GPR1 receptors, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.